Literature DB >> 30133334

Antimicrobial Resistance and Molecular Characterization of Extended-Spectrum β-Lactamases of Escherichia coli and Klebsiella spp. Isolates from Urinary Tract Infections in Southern Brazil.

Juliano Lacava Pereira1, Lisiane Martins Volcão1, Gabriel Baracy Klafke2, Roseli Stone Vieira3, Carla Vitola Gonçalves2, Ivy Bastos Ramis1, Pedro Eduardo Almeida da Silva1, Andrea von Groll1.   

Abstract

The objective of this study was to evaluate the frequency of different extended-spectrum β-lactamases (ESBL) as well as to associate these ESBL with antimicrobial (ATM) resistance in Escherichia coli and Klebsiella spp. isolates from outpatients and inpatients with urinary tract infections. The study included 435 consecutive nonduplicate clinical isolates, including 362 E. coli isolates, 62 Klebsiella pneumoniae isolates, and 11 K. oxytoca isolates. Isolates were obtained from patients who were treated in a University Hospital between August 2012 and July 2013. Three multiplex PCR were performed to identify the ESBL groups. A total of 48 (11%) ESBL-producing isolates were found. The risk for the ESBL presence was significantly higher in males (26.4%) than females (8%), from hospital-acquired infections (29.1%) than community-acquired infections (7.0%) and in Klebsiella spp. (27.4%) than in E. coli (7.7%). ESBL-producing isolates presented a significantly higher percentage of resistance in 21 of the 23 ATMs analyzed. The CTX-M-1 group was the most predominant ESBL identified. The blaCTX-M-1-group gene was found in 56% of the total ESBL producers from community and in 42.4% from hospital origins; it was followed in frequency by the blaCTX-M-8/25-group, also found in both environments. Klebsiella spp. presented the largest variety of β-lactamase enzyme combinations and a higher level of resistance to cefotaxime. These findings contribute to better knowledge of the epidemiology of ESBL enzymes and are alarming for the reduced therapeutic options available for the risk groups identified in the studied populations.

Entities:  

Keywords:  ESBL; antimicrobial resistance; multidrug resistance

Mesh:

Substances:

Year:  2018        PMID: 30133334      PMCID: PMC6441284          DOI: 10.1089/mdr.2018.0046

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  39 in total

1.  Cloning and sequence of the gene encoding a novel cefotaxime-hydrolyzing beta-lactamase (CTX-M-9) from Escherichia coli in Spain.

Authors:  M Sabaté; R Tarragó; F Navarro; E Miró; C Vergés; J Barbé; G Prats
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

2.  Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae.

Authors:  L Poirel; I Le Thomas; T Naas; A Karim; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 3.  Complicated urinary tract infections.

Authors:  M D Melekos; K G Naber
Journal:  Int J Antimicrob Agents       Date:  2000-08       Impact factor: 5.283

Review 4.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

5.  Rapid and simple detection of blaCTX-M genes by multiplex PCR assay.

Authors:  Li Xu; Vicki Ensor; Savita Gossain; Kathy Nye; Peter Hawkey
Journal:  J Med Microbiol       Date:  2005-12       Impact factor: 2.472

6.  Animal and human multidrug-resistant, cephalosporin-resistant salmonella isolates expressing a plasmid-mediated CMY-2 AmpC beta-lactamase.

Authors:  P L Winokur; A Brueggemann; D L DeSalvo; L Hoffmann; M D Apley; E K Uhlenhopp; M A Pfaller; G V Doern
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

7.  A novel CTX-M beta-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil.

Authors:  R Bonnet; J L Sampaio; R Labia; C De Champs; D Sirot; C Chanal; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

8.  Identification and characterization of a new porin gene of Klebsiella pneumoniae: its role in beta-lactam antibiotic resistance.

Authors:  A Doménech-Sánchez; S Hernández-Allés; L Martínez-Martínez; V J Benedí; S Albertí
Journal:  J Bacteriol       Date:  1999-05       Impact factor: 3.490

9.  Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240-->Gly.

Authors:  R Bonnet; C Dutour; J L Sampaio; C Chanal; D Sirot; R Labia; C De Champs; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 10.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

View more
  3 in total

1.  Multidrug-resistant Klebsiella pneumoniae: a retrospective study in Manaus, Brazil.

Authors:  Rafael Nakamura-Silva; Louise Cerdeira; Mariana Oliveira-Silva; Karen Regina Carim da Costa; Elder Sano; Bruna Fuga; Quézia Moura; Fernanda Esposito; Nilton Lincopan; Kelly Wyres; André Pitondo-Silva
Journal:  Arch Microbiol       Date:  2022-03-04       Impact factor: 2.667

Review 2.  Panorama of Bacterial Infections Caused by Epidemic Resistant Strains.

Authors:  João Victor de Oliveira Santos; Sérgio Dias da Costa Júnior; Sandrelli Meridiana de Fátima Ramos Dos Santos Medeiros; Iago Dillion Lima Cavalcanti; Jaqueline Barbosa de Souza; Davi Lacerda Coriolano; Wagner Roberto Cirilo da Silva; Maria Helena Menezes Estevam Alves; Isabella Macário Ferro Cavalcanti
Journal:  Curr Microbiol       Date:  2022-04-30       Impact factor: 2.343

Review 3.  Extended-Spectrum Beta-Lactamases Producing Escherichia coli in South America: A Systematic Review with a One Health Perspective.

Authors:  Carlos Bastidas-Caldes; Daniel Romero-Alvarez; Victor Valdez-Vélez; Roberto D Morales; Andrés Montalvo-Hernández; Cicero Gomes-Dias; Manuel Calvopiña
Journal:  Infect Drug Resist       Date:  2022-09-30       Impact factor: 4.177

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.